Clinical Trial: Universal STAR-T Cell Injection in Generalized Myasthenia Gravis

U.S., July 21 -- ClinicalTrials.gov registry received information related to the study (NCT07714798) titled 'Universal STAR-T Cell Injection in Generalized Myasthenia Gravis' on July 09.

Brief Summary: This is a Phase I, single-arm, open-label, dose-escalation and dose-expansion study.

This is an exploratory clinical study of universal STAR-T cell injection in patients with refractory generalized myasthenia gravis (GMG). Approximately 10-24 participants aged 18-65 years (inclusive) with the condition are planned to be enrolled.

The primary objective is to evaluate the safety, tolerability, preliminary efficacy, pharmacokinetic/pharmacodynamic (PK/PD) profile, and immunogenicity of universal STAR-T cell injection. The starting dose is 1.5...